U.S. Markets closed

Flaherty Financial Newsletter Spotlights "CEL-SCI Corporation's Global Phase 3 Cancer Immunotherapy Treatment Nearing the Finish Line" in Flaherty Financial Newsletter #60

WEST HARRISON, NY / ACCESSWIRE / November 14, 2017 / Take a new look at today's streamlined CEL-SCI Corporation (NYSE American: CVM) profile (sponsored) in this week's edition of Flaherty Financial Newsletter (#60). Shares are attractively low for new investors and only 11.8 million shares are outstanding. CEL-SCI's inspirational leader CEO Geert R. Kersten invested an additional $500,000 of his own family's funds so that his family's future is aligned even more with his the future of the shareholders. The current stock market value of recently around $20 million is ridiculously undervalued.

CEL-SCI is pioneering a revolutionary idea - treat the immune system of newly diagnosed cancer patients before it is debilitated by today's standard treatments of surgery, radiation, and/or chemotherapy. A string of positive events has happened. In August 2017, the FDA removed a chilling hold on CEL-SCI's Phase 3 study of its Multikine drug treatment for advanced primary head and neck cancer, thereby allowing that all clinical trial activities under the drug's Investigational New Drug Application could resume. In October, CEL-SCI was granted a European patent for Multkine's Mechanism of Action in making hiding cancer tumors visible to the immune system.

Consider CEL-SCI's issued or pending patents, its lead product Multikine's Orphan Drug Status, valuable U.S. manufacturing facilities, know-how crucial for turning out this complex immune system boosting biologic cancer drug treatment, its top notch partnerships, and its research pipeline with multibillion-dollar market potential.

Once there are 298 patient deaths in its pivotal world's largest study of head and neck cancer patients, results of the study can be tallied. Then, CEL-SCI will learn if the survival improvement meets the FDA benchmark of a 10% improvement in overall survival in patients who received Multkine plus the Standard of Care, over patients who received the Standard of Care alone. If successful, CEL-SCI expects to file for marketing approval around the world. Head and neck cancer is a large unmet need with a potential annual market in the billions. CEL-SCI's Multikine could become the first to be administered as part of a new Standard of Care for treating newly diagnosed head and neck cancer patients.

Beyond that triumph in the market, in the future Multikine treatment could be expanded beyond head and neck cancer to other solid cancers. Multikine's ability to activate the immune system could also work on viruses and other diseases.

Clearly, CEL-SCI is a truly late stage cancer biotech, but few have the vision to see most of the heavy lifting has been done. The finish line is nearly in sight. Most of the difficulties many Phase 3 and earlier Phases 1 and 2 biotech cancer companies have yet to face are behind CEL-SCI. Our point is that the odds of success are shifting in favor of CEL-SCI.

Our complete in depth sponsored CEL-SCI Corporation profile can be found archived on our Flaherty Financial News website at http://flahertyfinancialnews.com/.

Direct Link to Profile with Social Share Buttons:

http://campaign.r20.constantcontact.com/render?m=1101855435216&ca=e45406dd-7853-4bde-9421-0c64a9c04fcb

About Flaherty Financial News Inc.

Flaherty Financial News Inc. ("FFN") is the publisher of totally-electronic coverage of interesting public companies. FFN was launched in 2007 by the "legendary financial editor" Bob Flaherty, Editor and Chairman of Flaherty Financial News Inc., and his son Brian, President and Publisher. While previously serving as Chairman and Editor of Equities Magazine for twenty-five years and also Editor-in-Chief of Equities Special Situations, Bob had one of the most consistent and highest ranked long-run performance records measured by Hulbert Financial Digest. He is also an award-winning retired Senior Editor of Forbes Magazine, where he wrote 33 cover stories, two shy of the all-time Forbes record. He was also Chairman of The Over-The-Counter Securities Fund. Bob Flaherty is a Magna Cum Laude graduate of Harvard College in economics and also has an MBA with a Distinction in Finance from Harvard Business School. A former president of the New York Financial Writers' Association, Bob is a co-founder of their annual student scholarship program and, also co-founder of their annual award for significant long-term achievement in financial journalism.

Forward-Looking Statements:

This news release contains "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of l995) regarding the Flaherty Financial News Newsletter profile on CEL-SCI Corporation and its future business plans. These statements involve known and unknown risks and uncertainties, which may cause actual results and future achievements to be materially different than those implied by these forward-looking statements. Flaherty Financial News Inc. has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in their expectations of future events. Our full disclaimer and safe harbor statement appears in our Flaherty Financial News Newsletter #60.

Contact:

Flaherty Financial News Inc.
Robert J. Flaherty, Editor and Chairman
Phone: (914) 831-1151
http://www.flahertyfinancialnews.com

SOURCE: Flaherty Financial News Inc.